Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Print PDF (526K) Freely available
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Mignet, N.
Right arrow Articles by François, J.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mignet, N.
Right arrow Articles by François, J.-C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 2000, Vol. 28, No. 16 3134-3142
© 2000 Oxford University Press

The spherulitesTM: a promising carrier for oligonucleotide delivery

Nathalie Mignet1,2, Armelle Brun2, Corinne Degert2, Brigitte Delord3, Didier Roux3, Claude Hélène1, René Laversanne2 and Jean-Christophe François1,*

1Laboratoire de Biophysique, Muséum National d’Histoire Naturelle, INSERM U201, CNRS UMR 8646, 43 rue Cuvier, 75231 PARIS Cedex 05, France, 2Capsulis, S.A, Château Bersol, Bâtiment 1, 218/228 Avenue du Haut-Lévêque, 33600 PESSAC, France and 3Centre de Recherche Paul Pascal, Avenue du Dr A. Schweitzer, 33600 PESSAC, France

Concentric multilamellar microvesicles, named spherulitesTM, were evaluated as an oligonucleotide carrier. Up to 80% oligonucleotide was encapsulated in these vesicles. The study was carried out on two different spheruliteTM formulations. The spheruliteTM size and stability characteristics are presented. Delivery of encapsulated oligonucleotide was performed on a rat hepatocarcinoma and on a lymphoblastoid T cell line, both expressing the luciferase gene. We showed that spherulitesTM were able to transfect both adherent and suspension cell lines and deliver the oligonucleotide to the nucleus. Moreover, 48–62% luciferase inhibition was obtained in the rat hepatocarcinoma cell line when the antisense oligonucleotide targeted to the luciferase coding region was encapsulated at 500 nM concentration in spherulitesTM of different compositions.

* To whom correspondence should be addressed. Tel: +33 140 793 708; Fax: +33 140 793 705; Email: francois@cimrs1.mnhn.fr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.